Supernus Pharmaceuticals (SUPN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.53
- Estimate
- $0.51
- Surprise
- +4.1%
- Revenue (period 2026-06-30)
- $219.1M
- Score at report (before → after)
- 6.5 → 6.9/10
Revenue source: xbrl.
How the report landed
Supernus Pharmaceuticals (SUPN) beat the $0.51 estimate with diluted EPS of $0.53 — a clear 4.1% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.5/10) to Sell at 6.9/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates SUPN Sell at 6.2/10.
2 of the last 4 quarters beat the estimate; this quarter's +4.1% surprise compares with a +42.2% four-quarter average. Next scheduled report: 2026-11-03.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- Concentration risk — Customer: Cencora, Cardinal Health, and McKesson (76.0%)
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8)
- Consecutive earnings misses (2)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $43.90
- Price target
- $52.49
- Stop
- $41.55
- Upside to target
- +19.6%
- Reward-to-risk
- 3.3:1
Risk check: RSI 22 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
SUPN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $2.56B
- P/E (fwd)
- 9.9
- 52-week range
- $42.45–$59.68
- Off 52-week high
- 26.4%
- RSI (14)
- 22
- Volume vs avg
- 0.13×
- Score today
- 6.2/10